Some of these recurrent lesions observed in T-ALL are similar to those observed in other haematopoietic disorders such as precursor B-ALL—for example, the NUP214–ABL1 fusion.27,28 Tyrosine kinase inhibitors such as dasatinib and nilotinib are effective against BCR–ABL1-positive leukaemias and ABL-rearranged precursor B-ALL27,29,30 and show activity in vitro against NUP214–ABL1 T-ALL; however, clinical data are limited in this setting and further investigation is warranted.31–33. This evidence concerns the gene NUP214 and precursor B-cell acute lymphoblastic leukemia.